Skip to main content
SpringerLink
Log in

Troubles ostéoarticulaires: ostéoporose, arthralgies

  • Chapter
Aider á vivre aprés un cancer

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 387 Accesses

Résumé

Le pronostic du cancer du sein a largement bénéfi cié de son dépistage précoce et des progrés thérapeutiques qui permettent de guérir plus de trois femmes sur quatre quand la maladie reste localisée. La présence de récepteurs hormonaux rend un grand nombre de ces cancers sensibles à des thérapeutiques hormonomodulatrices, susceptibles de prévenir les récidives en détruisant les cellules malignes non détectables présentes au moment du diagnostic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Baum M, Budzar AU, Cuzick J, et al. (2002) ATAC Trialist’s Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: fi rst results of the ATAC randomised trial. Lancet 359: 2131–9

    Article  PubMed  CAS  Google Scholar 

  2. Eastell R, Hannon RA, Cuzick J, et al. (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. J Bone Miner Res 21: 1215–23

    Article  PubMed  CAS  Google Scholar 

  3. Eastell R, Adams JE, Coleman RE, et al. (2008) Effect of anastrozole on bone mineral density: 5 years results from the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 26(7): 1051–7

    Article  PubMed  CAS  Google Scholar 

  4. Jakesz R, Jonat W, Gnant M, et al. (2005) Switching of postmenopausal women with endocrine — responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455–62

    Article  PubMed  CAS  Google Scholar 

  5. Confavreux CB, Fontana A, Guastalla JP, et al. (2007) Estrogen-dependant increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41: 346–52

    Article  PubMed  CAS  Google Scholar 

  6. Forbes JF and the ATAC Trialist Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer; 100 month analysis of the ATAC trial. Lancet Oncol 9(1): 45–53

    Article  PubMed  CAS  Google Scholar 

  7. Goss PE, Ingle JN, Martino S, et al. (2003) A randomized trial of letrozole in postmenopausal women after fi ve years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–802

    Article  PubMed  CAS  Google Scholar 

  8. Goss PE, Ingle JN, Martino S, et al. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in positive receptor breast cancer: updated fi ndings from NCIC CTG MA-17. J Natl Cancer Instit 97: 1262–71

    Article  CAS  Google Scholar 

  9. Perez EA, Josse RG, Pritchard KI, et al. (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA-17. J Clin Oncol 24: 3629–35

    Article  PubMed  CAS  Google Scholar 

  10. Goss PE, Ingle JN, Pater JL, et al. (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26: 1948–55

    Article  PubMed  CAS  Google Scholar 

  11. Thurlimann BJ, Keshaviah A, Coates AS, et al. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1-98 collaborative Group. N Engl J Med 353: 2747–57

    Article  PubMed  Google Scholar 

  12. Coombes RC, Emma H, Gibson L, et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with early breast cancer. N Engl J Med 350: 1081–92

    Article  PubMed  CAS  Google Scholar 

  13. Coleman RE, Ranks LM, Girgis SI, et al. (2007) Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8: 119–27

    Article  PubMed  CAS  Google Scholar 

  14. Gonelli S, Cadimi A, Caffarelli C, et al. (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40: 205–10

    Article  CAS  Google Scholar 

  15. Goss PE, Chlebowski RT, Leboff MS, et al. (2006) Recommendations on bone health managements for women with early stage breast cancer. Am J Oncol Rev 5: 34–43

    Google Scholar 

  16. Gnant M, Mlineritsch H, Lushin-Ebengreuth G, et al. (2007) Zoledronic acid prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25(7): 820–8

    Article  PubMed  CAS  Google Scholar 

  17. Brufsky A, Harker W, Beck J, et al. (2007) Zoledronic acid inhibits adjuvant letrozoleinduced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 7: 829–36

    Article  CAS  Google Scholar 

  18. Greenspan SL, Bhattacharya RK, Sereika SM, et al. (2006) Prevention of Bone Loss in Survivors of Breast Cancer: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 92: 131–6

    Article  PubMed  CAS  Google Scholar 

  19. Lester JE, Gutcher SA, Ellis SP, et al. (2007) Monthly oral ibandronate prevents anastrozole-induced bone loss during adjuvant treatment for breast cancer. One year results from the ARIBON study. J Clin Oncol 25 (Abstract 553)

    Google Scholar 

  20. Donnellan PP, Douglas SL, Cameron DA, et al. (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19: 2767

    PubMed  CAS  Google Scholar 

  21. Morales L, Pans S, Paridaens R, et al. (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane associated tenosynovial changes on magnetic resonance imaging. Breast Canc Res Treat 104: 87–91

    Article  CAS  Google Scholar 

  22. Lebrun A, Briot K, Gligorov J, Roux C (2006) Douleurs articulaires liées aux inhibiteurs de l’aromatase: description de 26 cas. Rev Rhum 73: 1174 (Ma 79)

    Article  Google Scholar 

  23. Presant CA, Bosserman L, Young T, et al. (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7(10): 775–8

    Article  PubMed  CAS  Google Scholar 

  24. Crew KD, Greenlee H, Capodice J, et al. (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25: 3877–83

    Article  PubMed  Google Scholar 

  25. Henry NL, Giles JT, Ang D, et al. (2007) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111: 365–72

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Fontaine C, Meulemans C, Huizing M, et al. (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 2008 (in press)

    Google Scholar 

  27. Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52: 2594–8

    Article  PubMed  CAS  Google Scholar 

  28. Josse R (2007) Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment. Curr Opin Oncol 19(suppl 1): S1–S8

    Article  CAS  Google Scholar 

  29. Cutolo M, Lahita RG (2005) Estrogens and arthritis. Rheum Dis Clin North Am 31(1):19–27

    Article  PubMed  Google Scholar 

  30. Friedman AJ, Juneau-Norcross M, Rein MS (1993) Adverse effects of leuprolide acetate depot treatment. Fertil Steril 59: 448–50

    PubMed  CAS  Google Scholar 

  31. Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome Breast 16(3): 223–34

    Article  PubMed  Google Scholar 

  32. Blomqvist A (2000) Sex hormones and pain: a new role for brain aromatase? J Comp Neurol 423: 549–51

    Article  PubMed  CAS  Google Scholar 

  33. Laroche M, Borg S, Lassoued S, et al. (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjögren’s syndrome. J Rheumatol 34: 2259–63

    PubMed  CAS  Google Scholar 

  34. Shim GJ, Warner M, Kim HJ, et al. (2004) Aromatase-defi cient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren’s syndrome. Proc Natl Acad Sci USA 101(34): 12628–33

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  35. Morel B, Marotte H, Miossec P (2007) Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis 66: 557–8

    Article  PubMed Central  PubMed  Google Scholar 

  36. Thorne C (2007) Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Curr Opin Oncol 19 (suppl 1): S19–S28

    Article  CAS  Google Scholar 

  37. Buzdar A et the ATAC Trialist Group (2006) Clinical features of joint symptoms observed in the ATAC trial. ASCO 2006. J Clin Oncol 24(18S): abstract 551

    Article  Google Scholar 

  38. Thomas R, Godward S, Makris A, et al. (2004) Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, cross-over study, comaring letrozole with anastrozole. Clin Oncol 16(7): 485–91

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Médecine interne-rhumatologie, 79, avenue de Breteuil, 75015, Paris

    Pierre Khalifa

  2. Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511, Vandoeuvre-lés-Nancy

    Anne Lesur

Authors
  1. Pierre Khalifa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Lesur
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France

About this chapter

Cite this chapter

Khalifa, P., Lesur, A. (2010). Troubles ostéoarticulaires: ostéoporose, arthralgies. In: Aider á vivre aprés un cancer. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-79501-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-79501-5_14

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-79500-8

  • Online ISBN: 978-2-287-79501-5

Publish with us

Policies and ethics

Search

Navigation